MAPK3 and lung cancer: Our results indicated that 244-MPT effectively attenuated the phosphorylation of Akt and ERK1/2 in both wildtype and T790M mutant lung cancer cells and also reduced their viability and increased apoptosis compared with the traditional TKI, gefitinib (Figures 3, 4).